Inventiva SA reports €4.5 million revenue for first nine months of 2025
Inventiva SA reported €4.5 million in revenue for the first nine months of 2025, with cash and cash equivalents of €97.6 million and €24.7 million in short-term deposits as of September 30, 2025. The revenue included a $10 million milestone payment and $5 million in credit notes from Chia Tai Tianqing Pharmaceutical Group. The company expects its cash position to fund operations until early 2027, with potential extension if additional financing is secured.
Inventiva SA reported cash and cash equivalents of €97.6 million and €24.7 million in short-term deposits as of September 30, 2025. Revenues for the first nine months of 2025 reached €4.5 million, compared to none in the same period of 2024. The company’s revenues included a $10 million milestone payment and $5 million in credit notes from Chia Tai Tianqing Pharmaceutical Group under a license agreement. Net cash used in investing activities for the period was (€25.0) million, a change mainly due to variations in short-term deposits. Inventiva expects its cash position to fund operations until the end of the first quarter of 2027, or until mid-third quarter 2027 if additional financing is secured. Topline results from the NATiV3 study are expected in the second half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001140352-en) on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
